SOM Biotech

AltruBio to Present at Biotech Showcase Digital 2021

Wednesday, January 13, 2021 - 1:23pm

Redwood City, California--(Newsfile Corp. - January 13, 2021) - AltruBio Inc., www.altrubio.com , a clinical stage biotech company, today announced that it is participating in Biotech Showcase 2021, and providing an on-demand company presentation.

Key Points: 
  • Redwood City, California--(Newsfile Corp. - January 13, 2021) - AltruBio Inc., www.altrubio.com , a clinical stage biotech company, today announced that it is participating in Biotech Showcase 2021, and providing an on-demand company presentation.
  • AltruBio Inc., a clinical stage biotech company, today announced that it is participating in Biotech Showcase 2021, and providing an on-demand company presentation.
  • Dr. Judy Chou, President & CEO will be presenting AltruBio at Biotech Showcase Digital.
  • Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place.

NIBEC to Present at Biotech Showcase 2021

Monday, January 11, 2021 - 6:53pm

Seoul, South Korea--(Newsfile Corp. - January 11, 2021) - NIBEC Co., Ltd., today announced that it is participating in Biotech Showcase 2021 and providing an on-demand company presentation.

Key Points: 
  • Seoul, South Korea--(Newsfile Corp. - January 11, 2021) - NIBEC Co., Ltd., today announced that it is participating in Biotech Showcase 2021 and providing an on-demand company presentation.
  • This year registered attendees to Biotech Showcase can access recorded company presentations prior to the actual event.
  • NIBEC will present an overview of its peptide therapeutics discovery and delivery technology platform (TOPScovery) and its proprietary pipeline.
  • Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place.

Diverse Biotech announces orphan-drug designation for treatment of newly diagnosed glioblastoma

Monday, May 4, 2020 - 6:01pm

DOYLESTOWN, Pa., May 4, 2020 /PRNewswire/ --Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation.

Key Points: 
  • DOYLESTOWN, Pa., May 4, 2020 /PRNewswire/ --Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation.
  • For a drug to qualify for orphan designation both the drug and the disease or condition must meet certain criteria.
  • The orphan drug designation helps Diverse Biotech to advance our program, designed to combat such a terrible disease, and potentially improve the survival rates.
  • Diverse Biotech is a US-based biopharmaceutical company, focused on medical discoveries and the development of new molecules for the treatment of cancer and other debilitating diseases.

SOM Biotech Announces the In Vitro Confirmation of Three Drug Candidates for COVID-19 in Collaboration with the Ewha Womans University

Tuesday, April 21, 2020 - 4:47pm

BARCELONA, Spain, April 21, 2020 /PRNewswire/ -- SOM Biotech, a clinical-stage drug discovery and development company, announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19.

Key Points: 
  • BARCELONA, Spain, April 21, 2020 /PRNewswire/ -- SOM Biotech, a clinical-stage drug discovery and development company, announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19.
  • SOM Biotech has applied its artificial intelligence based screening technology (SOMAIPRO) to identify inhibitors of the 3CL proteases of SARS-CoV-2, SARS-CoV and MERS-CoV viruses as potential candidates to treat COVID-19.
  • The discoveries came as a result of the research conducted jointly by SOM Biotech and the Department of Pharmacy and Pharmaceutical Sciences led by Professor Dong-Hae Shin from Ewha Womans University in South Korea.
  • Within the three identified and validated drug candidates, one - Eravacycline - is an already approved drug.

SOM Biotech Announces the In Vitro Confirmation of Three Drug Candidates for COVID-19 in Collaboration with the Ewha Womans University

Tuesday, April 21, 2020 - 4:44pm

BARCELONA, Spain, April 21, 2020 /PRNewswire/ -- SOM Biotech, a clinical-stage drug discovery and development company, announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19.

Key Points: 
  • BARCELONA, Spain, April 21, 2020 /PRNewswire/ -- SOM Biotech, a clinical-stage drug discovery and development company, announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19.
  • SOM Biotech has applied its artificial intelligence based screening technology (SOMAIPRO) to identify inhibitors of the 3CL proteases of SARS-CoV-2, SARS-CoV and MERS-CoV viruses as potential candidates to treat COVID-19.
  • The discoveries came as a result of the research conducted jointly by SOM Biotech and the Department of Pharmacy and Pharmaceutical Sciences led by Professor Dong-Hae Shin from Ewha Womans University in South Korea.
  • Within the three identified and validated drug candidates, one - Eravacycline - is an already approved drug.